

DL-012998-03

January 29, 1998

Norfolk Community Hospital
ATTN: John D. Hopkins, Jr., M. D.
Radiation Safety Officer
2539 Corprew Avenue
Norfolk, VA 23504

SUBJECT: TRANSMITTAL AND EXPLANATION OF CORRECTED COPY OF AMENDMENT 12 TO
LICENSE NO. 45-12868-01 (DOCKET NO. 030-03360)

Dear Dr. Hopkins:

Enclosed please find a corrected copy of Amendment No. 12 to your NRC material license. Changes to the license are printed in **BOLD** typeface. This error was recently noted during a recent routine inspection.

Please review the document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify this office (ATTN: Ms. Diane Heim at (404) 562-4723) so that we can provide appropriate corrections and answers.

Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR 19, "Notice, Instructions and Reports to Workers; Inspections and Investigations," 10 CFR 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
 - a. when an authorized user, Radiation Safety Officer, or Teletherapy Physicist permanently discontinues performance of duties under the license or has a name change; or
 - b. when the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
 - a. when you decide to terminate all activities involving materials authorized under the license; or

- b. when you decide to terminate licensed activities in a separate building or outdoor area identified on your license; or
 - c. if you decide not to complete the facility, acquire equipment, or possess and use authorized material.
4. Request and obtain a license amendment before you:
- a. receive or use byproduct material for a clinical procedure permitted under 10 CFR 35 but not permitted by your license issued pursuant to this part.
 - b. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as an authorized user under a license for medical use of byproduct material;
 - c. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as a Radiation Safety Officer, Teletherapy Physicist, or Nuclear Pharmacist under a license for medical use of byproduct material;
 - d. order byproduct material in excess of the amount, or a different radionuclide or form, other than authorized on the license;
 - e. add or change the areas of use or address (or addresses) of use identified in the license application or on the license; or
 - f. change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. Transfer of licensed materials must be consistent with 10 CFR 30.41, 40.51 or 70.42, as applicable. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a Notice of Violation, or imposition of a Civil Penalty, or an order suspending, modifying or revoking your license as specified in the "General Statement of Policy and Procedures for NRC Enforcement Actions," NUREG-1600, (7/95). Since

serious consequences to employees and the public can result from failure to comply with NRC requirements. prompt and vigorous enforcement action will be taken against those who do not achieve the necessary attention to detail and standard of compliance expected of licensees.


Thank you for your cooperation.

Sincerely,



John M. Pelchat, License Reviewer
Division of Nuclear Materials Safety

- Enclosures: 1. Corrected Copy of Amendment No. 12.
License No. 45-12768-01
2. NRC Form 313

OFFICE	RTT:DNB	RTT:DNB	RTT:DNB							
SIGNATURE										
NAME	J. Pelchat	Decker	Decker							
DATE	1/4/98	1/ /98	1/30/98	1/ /98	1/ /98	1/ /98	1/ /98	1/ /98	1/ /98	1/ /98
COPY?	YES NO	YES NO	YES (NO)	YES NO						

OFFICIAL RECORD COPY

MATERIALS LICENSE

Amendment No. 12

CORRECTED COPY

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Norfolk Community Hospital</p> <p>2. 2539 Corprew Avenue</p> <p>Norfolk, Virginia 23504</p>	<p>In accordance with letter dated January 4, 1995</p> <p>3. License number 45-12768-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date January 31, 2001</p> <hr/> <p>5. Docket No. 030-03360 Reference No.</p>
---	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.500	C. Any diagnostic source identified in 10 CFR 35.500 in a compatible device registered pursuant to 10 CFR 32.210 or an equivalent Agreement State regulation	C. As needed
D. Iodine 131	D. Sodium iodide radiopharmaceutical in capsule form only	D. As needed (not to exceed 10 curies)
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed

9. Authorized Use:
- A. Medical use described in 10 CFR 35.100.
 - B. Medical use described in 10 CFR 35.200.
 - C. Medical use described in 10 CFR 35.500.
 - D. Treatment of hyperthyroidism and cardiac dysfunction.
 - E. In vitro studies.

2/1

9802190238 980128
PDR ADOCK 03003360
C PDR



ML 28

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

45-12768-01

Docket or Reference Number

030-03360

Amendment No. 12

CONDITIONS

10. Location for use: Norfolk Community Hospital, 2539 Corprew Avenue, Norfolk, Virginia.
11. Radiation Safety Officer: John D. Hopkins, Jr., M.D.
12. Authorized user(s):
- A. John D. Hopkins, M.D. Medical uses identified in 10 CFR 35.100, 35.200, 35.500, iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction, and in vitro testing.
- B. Paul C. Davis, M.D. Medical uses identified in 10 CFR 35.100, 35.200, 35.500, iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction, and in vitro testing.
13. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.
14. The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facilities listed in Condition 10 pursuant to the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-12768-01

Docket or Reference Number
030-03360

Amendment No. 12

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated February 9, 1990

B. Letters dated:

- (1) February 4, 1991
- (2) July 16, 1992
- (3) January 4, 1995 [relocation of nuclear medicine operations to formerly occupied area.]
- (4) March 1, 1996 [extend expiration date in accordance with 10 CFR 30.36]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

JOHN M. PELCHAT

DATE

JAN 23 1998

BY



Region II, Division of Nuclear Materials Safety
61 Forsyth Street, Suite 23T85
Atlanta, GA 30303

NACTIVEM5-12768 C12

Handwritten signature
1/29/98